The role of gemtuzumab ozogamicin in acute leukaemia therapy.

@article{Tsimberidou2006TheRO,
  title={The role of gemtuzumab ozogamicin in acute leukaemia therapy.},
  author={Apostolia-Maria Tsimberidou and Francis J Giles and Elihu Estey and Susan M O'Brien and Michael J Keating and Hagop M Kantarjian},
  journal={British journal of haematology},
  year={2006},
  volume={132 4},
  pages={398-409}
}
Gemtuzumab ozogamicin (GO) is an immunoconjugate that binds to CD33 on the surface of acute myeloid leukaemia (AML) blasts and, after internalisation, releases a cytotoxic drug, calicheamicin. GO is approved by the US Food and Drug Administration for the treatment of CD33-positive AML at first relapse in patients 60 years and older who are not candidates for other cytotoxic therapy. GO as a single agent has low antileukaemic activity. When given to patients meeting the criteria noted above, it… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Similar Papers

Loading similar papers…